Innoviva Company Profile (NASDAQ:THRX)

About Innoviva (NASDAQ:THRX)

Innoviva logoInnoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:THRX
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $9.81
  • 200 Day Moving Avg: $11.67
  • 52 Week Range: $6.36 - $21.16
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 32.70
  • P/E Growth: 0.00
  • Net Margins: 60.02%
  • Return on Assets: 36.91%
  • Average Volume: 867,484 shs.

Frequently Asked Questions for Innoviva (NASDAQ:THRX)

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "THRX."

Who are some of Innoviva's key competitors?

Who are Innoviva's key executives?

Innoviva's management team includes the folowing people:

  • William H. Waltrip, Independent Chairman of the Board
  • Eric D'Esparbes, Chief Financial Officer, Senior Vice President
  • Theodore J. Witek Jr., Senior Vice President, Chief Scientific Officer
  • Michael E. Faerm, Senior Vice President and Chief Business Officer
  • Michael W. Aguiar, President, Chief Executive Officer, Director
  • Barbara G. Duncan, Independent Director
  • Catherine J. Friedman, Independent Director
  • Patrick G. LePore, Independent Director
  • Paul A. Pepe, Independent Director

How do I buy Innoviva stock?

Shares of Innoviva can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Innoviva's stock price today?

One share of Innoviva stock can currently be purchased for approximately $9.81.

MarketBeat Community Rating for Innoviva (NASDAQ THRX)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  26 (Vote Outperform)
Underperform Votes:  22 (Vote Underperform)
Total Votes:  48
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Innoviva (NASDAQ:THRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Innoviva (NASDAQ:THRX)
Price Target History for Innoviva (NASDAQ:THRX)
Analysts' Ratings History for Innoviva (NASDAQ:THRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/2/2016Morgan StanleyReiterated RatingSell$7.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for Innoviva (NASDAQ:THRX)
No earnings announcements for this company have been tracked by


Earnings Estimates for Innoviva (NASDAQ:THRX)
Current Year EPS Consensus Estimate: $-0.19 EPS
Next Year EPS Consensus Estimate: $0.30 EPS


Dividend History for Innoviva (NASDAQ:THRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Innoviva (NASDAQ:THRX)
No insider trades for this company have been tracked by


Headline Trends for Innoviva (NASDAQ:THRX)
Latest Headlines for Innoviva (NASDAQ:THRX)



Innoviva (THRX) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.